Compare TPC & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPC | CRSP |
|---|---|---|
| Founded | 1894 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | General Bldg Contractors - Nonresidential Bldgs | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.8B |
| IPO Year | 2003 | 2016 |
| Metric | TPC | CRSP |
|---|---|---|
| Price | $81.07 | $48.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 23 |
| Target Price | ★ $116.25 | $74.33 |
| AVG Volume (30 Days) | 397.5K | ★ 1.4M |
| Earning Date | 11-04-2026 | 11-02-2026 |
| Dividend Yield | ★ 0.43% | N/A |
| EPS Growth | ★ 148.24 | N/A |
| EPS | ★ 2.09 | N/A |
| Revenue | ★ $5,543,039,000.00 | $289,590,000.00 |
| Revenue This Year | $15.10 | $1,091.30 |
| Revenue Next Year | $12.66 | $216.80 |
| P/E Ratio | $48.47 | ★ N/A |
| Revenue Growth | 28.11 | ★ 9169.85 |
| 52 Week Low | $57.90 | $44.12 |
| 52 Week High | $102.30 | $63.45 |
| Indicator | TPC | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 53.06 | 49.65 |
| Support Level | $80.63 | $50.02 |
| Resistance Level | $88.92 | $60.68 |
| Average True Range (ATR) | 2.96 | 2.33 |
| MACD | 0.61 | 0.21 |
| Stochastic Oscillator | 78.80 | 52.19 |
Tutor Perini Corp offers general contracting, construction management, and design-build services to private and public customers. The company constructs and repairs transportation infrastructure, water-treatment facilities, and a wide range of buildings. Tutor Perini has three operating segments: Civil, Building, and Specialty Contractors. A majority of its revenue is generated from the Civil segment, which specializes in public works construction and the replacement and reconstruction of infrastructure. Its civil contracting services include construction and rehabilitation of highways, bridges, tunnels, mass-transit systems, military and other government facilities, and water management and wastewater treatment facilities. Geographically it derives key revenue from the United States.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.